Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer

Rouzbeh Daylami, Diego J. Muilenburg, Subbulakshmi Virudachalam, Richard J Bold

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Pancreatic ductal adenocarcinoma has proven to be one of the most chemo-resistant among all solid organ malignancies. Several mechanisms of resistance have been described, though few reports of strategies to overcome this chemo-resistance have been successful in restoring sensitivity to the primary chemotherapy (gemcitabine) and enter the clinical treatment arena. Methods: We examined the ability of cellular arginine depletion through treatment with PEG-ADI to alter in vitro and in vivo cytotoxicity of gemcitabine. The effect on levels of key regulators of gemcitabine efficacy (e.g. RRM2, hENT1, and dCK) were examined. Results: Combination of PEG-ADI and gemcitabine substantially increases growth arrest, leading to increased tumor response in vivo. PEG-ADI is a strong inhibitor of the gemcitabine-induced overexpression of ribonucleotide reductase subunit M2 (RRM2) levels both in vivo and in vitro, which is associated with gemcitabine resistance. This mechanism is through the abrogation of the gemcitabine-mediated inhibitory effect on E2F-1 function, a transcriptional repressor of RRM2. Conclusion: The ability to alter gemcitabine resistance in a targeted manner by inducing metabolic stress holds great promise in the treatment of advanced pancreatic cancer.

Original languageEnglish (US)
Article number102
JournalJournal of Experimental and Clinical Cancer Research
Volume33
Issue number1
DOIs
StatePublished - 2014

Fingerprint

gemcitabine
Pancreatic Neoplasms
Physiological Stress
ADI PEG20
Arginine
Neoplasms

Keywords

  • Gemcitabine
  • Pancreatic cancer
  • PEG-ADI
  • RRM2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. / Daylami, Rouzbeh; Muilenburg, Diego J.; Virudachalam, Subbulakshmi; Bold, Richard J.

In: Journal of Experimental and Clinical Cancer Research, Vol. 33, No. 1, 102, 2014.

Research output: Contribution to journalArticle

@article{0705b6d1e8e14318bad532f03039cd4d,
title = "Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer",
abstract = "Background: Pancreatic ductal adenocarcinoma has proven to be one of the most chemo-resistant among all solid organ malignancies. Several mechanisms of resistance have been described, though few reports of strategies to overcome this chemo-resistance have been successful in restoring sensitivity to the primary chemotherapy (gemcitabine) and enter the clinical treatment arena. Methods: We examined the ability of cellular arginine depletion through treatment with PEG-ADI to alter in vitro and in vivo cytotoxicity of gemcitabine. The effect on levels of key regulators of gemcitabine efficacy (e.g. RRM2, hENT1, and dCK) were examined. Results: Combination of PEG-ADI and gemcitabine substantially increases growth arrest, leading to increased tumor response in vivo. PEG-ADI is a strong inhibitor of the gemcitabine-induced overexpression of ribonucleotide reductase subunit M2 (RRM2) levels both in vivo and in vitro, which is associated with gemcitabine resistance. This mechanism is through the abrogation of the gemcitabine-mediated inhibitory effect on E2F-1 function, a transcriptional repressor of RRM2. Conclusion: The ability to alter gemcitabine resistance in a targeted manner by inducing metabolic stress holds great promise in the treatment of advanced pancreatic cancer.",
keywords = "Gemcitabine, Pancreatic cancer, PEG-ADI, RRM2",
author = "Rouzbeh Daylami and Muilenburg, {Diego J.} and Subbulakshmi Virudachalam and Bold, {Richard J}",
year = "2014",
doi = "10.1186/s13046-014-0102-9",
language = "English (US)",
volume = "33",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer

AU - Daylami, Rouzbeh

AU - Muilenburg, Diego J.

AU - Virudachalam, Subbulakshmi

AU - Bold, Richard J

PY - 2014

Y1 - 2014

N2 - Background: Pancreatic ductal adenocarcinoma has proven to be one of the most chemo-resistant among all solid organ malignancies. Several mechanisms of resistance have been described, though few reports of strategies to overcome this chemo-resistance have been successful in restoring sensitivity to the primary chemotherapy (gemcitabine) and enter the clinical treatment arena. Methods: We examined the ability of cellular arginine depletion through treatment with PEG-ADI to alter in vitro and in vivo cytotoxicity of gemcitabine. The effect on levels of key regulators of gemcitabine efficacy (e.g. RRM2, hENT1, and dCK) were examined. Results: Combination of PEG-ADI and gemcitabine substantially increases growth arrest, leading to increased tumor response in vivo. PEG-ADI is a strong inhibitor of the gemcitabine-induced overexpression of ribonucleotide reductase subunit M2 (RRM2) levels both in vivo and in vitro, which is associated with gemcitabine resistance. This mechanism is through the abrogation of the gemcitabine-mediated inhibitory effect on E2F-1 function, a transcriptional repressor of RRM2. Conclusion: The ability to alter gemcitabine resistance in a targeted manner by inducing metabolic stress holds great promise in the treatment of advanced pancreatic cancer.

AB - Background: Pancreatic ductal adenocarcinoma has proven to be one of the most chemo-resistant among all solid organ malignancies. Several mechanisms of resistance have been described, though few reports of strategies to overcome this chemo-resistance have been successful in restoring sensitivity to the primary chemotherapy (gemcitabine) and enter the clinical treatment arena. Methods: We examined the ability of cellular arginine depletion through treatment with PEG-ADI to alter in vitro and in vivo cytotoxicity of gemcitabine. The effect on levels of key regulators of gemcitabine efficacy (e.g. RRM2, hENT1, and dCK) were examined. Results: Combination of PEG-ADI and gemcitabine substantially increases growth arrest, leading to increased tumor response in vivo. PEG-ADI is a strong inhibitor of the gemcitabine-induced overexpression of ribonucleotide reductase subunit M2 (RRM2) levels both in vivo and in vitro, which is associated with gemcitabine resistance. This mechanism is through the abrogation of the gemcitabine-mediated inhibitory effect on E2F-1 function, a transcriptional repressor of RRM2. Conclusion: The ability to alter gemcitabine resistance in a targeted manner by inducing metabolic stress holds great promise in the treatment of advanced pancreatic cancer.

KW - Gemcitabine

KW - Pancreatic cancer

KW - PEG-ADI

KW - RRM2

UR - http://www.scopus.com/inward/record.url?scp=84965191759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965191759&partnerID=8YFLogxK

U2 - 10.1186/s13046-014-0102-9

DO - 10.1186/s13046-014-0102-9

M3 - Article

VL - 33

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 102

ER -